This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Abbottic, Clarithromycin, Biaxin XL, Biclar, Celex, Clarith, Cyllind, Heliclar, Klacid, Klaricid, Kofron, Maclar, Macladin, Mavid, MonoZeclar, Naxy, Zeclar
Description: Biaxin (Clarithromycin) is a semi-synthetic macrolide antibiotic that inhibits bacterial protein synthesis at the 50S ribosome.Biaxin exhibits good activity against atypicals, Haemophilus influenzae, Moraxella catarrhalis, Helicobacter pylori, and Mycobacterium avium; moderate activity against Streptococcus pneumoniae and Streptococcus pyogenes; and poor activity against staphylococci, anaerobes, and enterococci.
Biaxin was licensed from Taisho Pharmaceuticals Company of Japan and developed by Abbott.
Abbott and AbbVie
In October 2011, Abbott announced plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. The diversified medical products company will consist of Abbott's existing diversified medical products portfolio, including its branded generic pharmaceutical, devices, diagnostic and nutritional businesses, and will retain the Abbott name. The research-based pharmaceutical company will include Abbott's current portfolio of proprietary pharmaceuticals and biologics and will be named AbbVie. The transaction is expected to be completed by the end of 2012.
In January 2013, Abbott completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. Abbott and AbbVie will share marketing rights on certain products....See full deal structure in Biomedtracker
Partners: Taisho Pharmaceutical Co., Ltd. Abbott Laboratories
Pink Sheet Abbott scrutinizes Sandoz’ Biaxin generics
Pink Sheet In Brief: Abbott's Biaxin
Additional information available to subscribers only: